- Home
- AMPH
as 04-23-2025 4:00pm EST
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RANCHO CUCAMONGA |
| Market Cap: | 1.2B | IPO Year: | 2014 |
| Target Price: | $43.50 | AVG Volume (30 days): | 670.7K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.06 | EPS Growth: | 17.69 |
| 52 Week Low/High: | $22.64 - $53.96 | Next Earning Date: | 05-07-2025 |
| Revenue: | $731,967,000 | Revenue Growth: | 13.59% |
| Revenue Growth (this year): | 2.15% | Revenue Growth (next year): | 6.64% |
Stock Insider Trading Activity of Amphastar Pharmaceuticals Inc. (AMPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Petersen Floyd F. | AMPH | Director | Apr 1 '25 | Sell | $28.38 | 500 | $14,190.25 | 73,909 | |
| Petersen Floyd F. | AMPH | Director | Mar 6 '25 | Sell | $27.99 | 1,000 | $27,986.30 | 73,909 | |
| PETERS WILLIAM J | AMPH | CFO, EVP & TREASURER | Mar 4 '25 | Sell | $27.54 | 4,231 | $116,515.39 | 97,363 |
Latest Amphastar Pharmaceuticals Inc. News
AMPH Breaking Stock News: Dive into AMPH Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
BofA Adjusts Price Target on Amphastar Pharmaceuticals to $31 From $36
Argus Research
8 days ago
AMPH: What does Argus have to say about AMPH?
Insider Monkey
9 days ago
Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?
StockStory
9 days ago
2 Reasons to Like AMPH and 1 to Stay Skeptical
Simply Wall St.
13 days ago
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Argus Research
15 days ago
AMPH: Lowering target price to $26.00
ACCESS Newswire
21 days ago
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Argus Research
22 days ago
AMPH: What does Argus have to say about AMPH?
Compare AMPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMPH Amphastar Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.